Business Desk :
Bangladesh’s leading manufacturer and exporter of medicine Beximco Pharmaceuticals Limited (“Beximco Pharma” or “the Company”; AIM Symbol: BXP) today announces that it has received approval for its Methocarbamol tablets (500 mg and 750 mg) from the US Food and Drug Administration (US FDA). This is generic equivalent to muscle relaxant drug Robaxin tablets (500 mg and 750 mg) from Auxilium Pharmaceutcials, LLC, said a press release.
This is the fourth ANDA approval for the Company in the US market and it expects to launch the product during last quarter of 2017. According to IMS, currently there are 4 active generic players for Methocarbamol in the USA, namely Camber, Qualitest, West-Ward and Solco.
Commenting on the approval, the managing director of the Company Mr. Nazmul Hassan MP says, “We are delighted to have our 4th ANDA approved by the US FDA. I firmly believe this approval and our growing pipeline for US will largely help us build our presence in the world’s largest pharma market in the coming years.”
Beximco Pharma became the first Bangladeshi pharmaceutical company audited and approved by the US FDA in June 2015.
The Company currently has a global footprint in more than 50 countries and has been accredited by a number of global regulatory authorities, including US FDA, AGES (EU), TGA Australia, Health Canada, GCC and TFDA.
